Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Infectious Disease Reports
Published in: Current Infectious Disease Reports 3/2010

01-05-2010

Pulmonary Nontuberculous Mycobacterial Disease: New Insights into Risk Factors for Susceptibility, Epidemiology, and Approaches to Management in Immunocompetent and Immunocompromised Patients

Authors: Paul Saleeb, Kenneth N. Olivier

Published in: Current Infectious Disease Reports | Issue 3/2010

Login to get access

Abstract

Nontuberculous mycobacteria (NTM) are ubiquitous in the environment and cause a wide range of diseases in humans. Pulmonary involvement, the most common disease manifestation of NTM infection, is being increasingly encountered in clinical settings. In addition, specific phenotypic and genetic characteristics of persons predisposed to contract pulmonary NTM disease are now beginning to be recognized. Prior to treatment, patients should meet clinical and microbiologic criteria for NTM disease. Treatment involves prolonged courses of antibiotics in various combination regimens that are often discontinued because of serious side effects. In some cases, complete cure of pulmonary disease is difficult to achieve. Rather, clinical improvement may be a more feasible goal. Surgical treatment is warranted for select patients.
Literature
1.
•• Griffith DC, Aksamit T, Brown-Elliott BA, et al.: An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007, 175:367–416. This article provides the most up-to-date official guidelines for the diagnosis and management of pulmonary infections caused by nontuberculous mycobacteria endorsed by the American Thoracic Society and the Infectious Diseases Society of America.
2.
Marras TK, Chedore P, Ying AM, et al.: Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997–2003. Thorax 2007, 62:661–666.CrossRefPubMed
3.
Khan K, Wang J, Marras TK: Nontuberculous mycobacterial sensitization in the United States: national trends over three decades. Am J Respir Crit Care Med 2007, 176:306–313.CrossRefPubMed
4.
Billinger ME, Olivier KN, Viboud C, et al.: Nontuberculous mycobacteria-associated lung disease in hospitalized persons, United States, 1998–2005. Emerging Infect Dis 2009, 15:1562–1569.PubMed
5.
Edwards LB, Acquaviva FA, Livesay VT, et al.: An atlas of sensitivity to tuberculin, PPD-B, and histoplasmin in the United States. Am Rev Respir Dis 1969, 99(Suppl):1–132.
6.
Kirschner R, Parker B, Falkinham J: Epidemiology of infection by nontuberculous mycobacteria: Mycobacterium avium, Mycobacterium intracellulare, and Mycobacterium scrofulaceum in acid, brown-water swamps of the Southeastern United States and their association with environmental variables. Am Rev Respir Dis 1992, 145:271–275.PubMed
7.
Aksamit TR: Mycobacterium avium complex pulmonary disease in patients with pre-existing lung disease. Clin Chest Med 2002, 23:643–653.CrossRefPubMed
8.
Noone PG, Leigh MW, Sannuti A, et al.: Primary ciliary dyskinesia: diagnostic and phenotypic features. Am J Respir Crit Care Med 2004, 169:459–467.CrossRefPubMed
9.
Olivier KN, Weber DJ, Wallace RJ, et al.: Nontuberculous mycobacteria: 1. Multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003, 167:828–834.CrossRefPubMed
10.
Ebert DL, Olivier KN: Nontuberculous mycobacteria in the setting of cystic fibrosis. Clin Chest Med 2002, 23:655–663.CrossRefPubMed
11.
Melia E, Freeman AF, Shea YR, et al.: Pulmonary nontuberculous mycobacterial infections in hyper-IgE syndrome. J Allergy Clin Immunol 2009, 124:617–618.CrossRefPubMed
12.
Reich JM, Johnson RE: Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern: the Lady Windermere syndrome. Chest 1992, 101:1605–1609.CrossRefPubMed
13.
Dhillon SS, Watanakunakorn C: Lady Windermere syndrome: middle lobe bronchiectasis and Mycobacterium avium complex infection due to voluntary cough suppression. Clin Infect Dis 2000, 30:572–575.CrossRefPubMed
14.
• Kim RD, Greenberg DE, Ehrmantraut ME, et al.: Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008, 178:1066–1074. This article provides an excellent study of the phenotypic characteristics of women without underlying pulmonary disease who develop pulmonary nontuberculous mycobacterial disease.
15.
Colombo RE, Hill SC, Claypool RJ, et al.: Familial clustering of pulmonary nontuberculous mycobacterial disease. Chest 2009, Epub ahead of print..
16.
Freeman AF, Olivier KN, Rubio TT, et al.: Intrathoracic nontuberculous mycobacterial infections in otherwise healthy children. Pediatr Pulmonol 2009, 44:1051–1056.CrossRefPubMed
17.
•• Colombo RE, Olivier KN: Diagnosis and treatment of infections caused by rapidly growing mycobacteria. Semin Respir Crit Care Med 2008, 29:577–588. This article provides a review of the spectrum of disease and management of infection due to rapidly growing mycobacteria, especially Mycobacterium abscessus.
18.
Bange FC, Bottger EC: Improved decontamination method for recovering mycobacteria from patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2002, 21:546–548.CrossRefPubMed
19.
Nishimura T, Hasegawa N, Fujita Y, et al.: Serodiagnostic contributions of antibody titers against mycobacterial lipid antigens in Mycobacterium avium complex pulmonary disease. Clin Infect Dis 2009, 49:529–535.CrossRefPubMed
20.
Ballarino GB, Olivier KN, Claypool RJ, et al.: Pulmonary nontuberculous mycobacterial infections: antibiotic treatment and associated costs. Respir Med 2009, 103:1448–1455.CrossRefPubMed
21.
Wallace RJ, Zhang Y, Brown BA, et al.: Polyclonal Mycobacterium avium complex infections in patients with nodular bronchiectasis. Am J Respir Crit Care Med 1998, 158:1235–1244.PubMed
22.
Research Committee of the British Thoracic Society: Pulmonary disease caused by Mycobacterium avium-intracellulare in HIV-negative patients: five-year follow-up of patients receiving standardized treatment. Int J Tuberc Lung Dis 2002, 6:628–634.
23.
Wallace RJ Jr, Brown BA, Griffith DE, et al.: Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med 1994, 149:1335–1341.PubMed
24.
Griffith DE, Brown BA, Girard WM, et al.: Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus. Clin Infect Dis 1996, 23:983–989.PubMed
25.
Griffith DE, Brown-Elliott BA, Longsjoen B, et al.: Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006, 174:928–934.CrossRefPubMed
26.
Lam PK, Griffith DE, Aksamit TR, et al.: Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006, 173:128–1289.CrossRef
27.
Pezzia W, Raleigh JW, Bailey MC, et al.: Treatment of pulmonary disease due to Mycobacterium kansasii: recent experience with rifampin. Rev Infect Dis 1981, 3:1035–1039.PubMed
28.
Banks J, Hunter AM, Campbell IA, et al.: Pulmonary infection with Mycobacterium kansasii in Wales, 1970–79: review of treatment and response. Thorax 1983, 38:271–274.CrossRefPubMed
29.
Nash KA, Brown-Elliott BA, Wallace RJ: A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009, 53:1367–1376.CrossRefPubMed
30.
Jeon K, Jung Kwon O, Lee NY, et al.: Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009, 180:896–902.
31.
Brown-Elliott BA, Crist CJ, Mann LB, et al.: In vitro activity of linezolid against slowly growing nontuberculous mycobacteria. Antimicrob Agents Chemother 2003, 47:1736–1738.CrossRefPubMed
32.
Cavusoglu C, Soyler I, Akinci P: Activities of linezolid against nontuberculous mycobacteria. New Microbiol 2007, 30:411–414.PubMed
33.
Chalermskulrat W, Sood N, Neuringer IP, et al.: Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax 2006, 61:507–513.CrossRefPubMed
34.
Zaidi S, Elidemir O, Heinle JS, et al.: Mycobacterium abscessus in cystic fibrosis lung transplant recipients: report of 2 cases and risk for recurrence. Transpl Infect Dis 2009, 11:243–248.CrossRefPubMed
Metadata
Title
Pulmonary Nontuberculous Mycobacterial Disease: New Insights into Risk Factors for Susceptibility, Epidemiology, and Approaches to Management in Immunocompetent and Immunocompromised Patients
Authors
Paul Saleeb
Kenneth N. Olivier
Publication date
01-05-2010
Publisher
Current Science Inc.
Published in
Current Infectious Disease Reports / Issue 3/2010
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-010-0103-6

Other articles of this Issue 3/2010

Current Infectious Disease Reports 3/2010 Go to the issue

ReviewPaper

H1N1 Influenza Pandemic of 2009 Compared With Other Influenza Pandemics: Epidemiology, Diagnosis, Management, Pulmonary Complications, and Outcomes

ReviewPaper

Aspergillus Infections in the Head and Neck

ReviewPaper

Influenza in Travelers: Epidemiology, Risk, Prevention, and Control Issues

ReviewPaper

Global Impact of Multidrug-Resistant Pulmonary Tuberculosis Among HIV-Infected and Other Immunocompromised Hosts: Epidemiology, Diagnosis, and Strategies for Management

ReviewPaper

Drug-Resistant Malaria: The Era of ACT

ReviewPaper

Update on Dengue: Epidemiology, Virus Evolution, Antiviral Drugs, and Vaccine Development
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits